ZNF875

Across TCGA pan-cancer cohorts, ZNF875 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF875 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ZNF875 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF875 expression acts as an unfavorable survival marker.

DLBC, STAD, and PRAD are the cancer types where ZNF875 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
STAD	DFS	Median	All	0.282	0.722	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF875–DLBC (OS)

Open the DLBC breakdown →